Known targets — ChEMBL curated mechanism
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
The experimentally established mechanism targets of Acyclovir. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 7/20 | 0.91 |
| ▸ | BLM | P54132 | 2/20 | 0.91 |
| ▸ | HBB | P68871 | 2/20 | 0.91 |
| ▸ | USP2 | O75604 | 1/20 | 0.91 |
| ▸ | TSHR | P16473 | 1/20 | 0.91 |
| ▸ | EDNRA | P25101 | 1/20 | 0.91 |
| ▸ | HTR2A | P28223 | 1/20 | 0.91 |
| ▸ | RECQL | P46063 | 1/20 | 0.91 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.91 |
| ▸ | HPRT1 | P00492 | 7/20 | 0.81 |
| ▸ | POLG | P54098 | 2/20 | 0.73 |
| ▸ | MEN1 | O00255 | 2/20 | 0.64 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.64 |
| ▸ | LMNA | P02545 | 1/20 | 0.64 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.64 |
| ▸ | VCP | P55072 | 1/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.64 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acyclovir SCHEMBL543440 | 1.00 | PNP (0.91) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL145614 | 1.00 | PNP (0.91) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL23440044 | 1.00 | PNP (0.91) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL11310314 | 0.99 | PNP (0.88) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL28326009 | 0.99 | PNP (0.88) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL11310318 | 0.99 | PNP (0.88) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL571377 | 0.95 | PNP (0.86) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL6917017 | 0.95 | PNP (0.86) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3664893 | 0.95 | PNP (1.00) | PNPBLMHBBUSP2TSHR | |
| Acyclovir SCHEMBL3175 | 0.95 | PNP (1.00) | PNPBLMHBBUSP2TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 322 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024158704-A1 | COMPOSITIONS AND METHODS FOR IMPROVING THE SOLUBILITY OF DRUGS AND COMPOUNDS | Villya LLC (US) | 2024-08-02 | — | — | WO | claimed |
| EP-4190312-A1 | SYNERGISTIC TRANSPORT OF LIPOPHILIC AND HYDROPHILIC ACTIVE AGENTS INTO NANOPARTICLES | Karlsruher Institut für Technologie (DE) | 2023-06-07 | — | — | EP | claimed |
| US-9549930-B2 | Combined systemic and topical treatment of disordered and/or prodromal stage tissue | QUADEX PHARMACEUTICALS, LLC (US) | 2017-01-24 | — | — | US | claimed |
| US-9545408-B2 | Combined systemic and topical treatment of disordered tissues | QUADEX PHARMACEUTICALS, INC. (US) | 2017-01-17 | — | — | US | claimed |
| US-9393212-B2 | Nanocrystals, compositions, and methods that aid particle transport in mucus | KALA PHARMACEUTICALS, INC. (US) | 2016-07-19 | — | — | US | claimed |
| US-20150246137-A1 | LIPID COATED NANOPARTICLES CONTAINING AGENTS HAVING LOW AQUEOUS AND LIPID SOLUBILITIES AND METHODS THEREOF | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-09-03 | — | — | US | claimed |
| US-20090176743-A1 | Methods for treating or preventing reactivation of a latent herpesvirus infection | BETH ISRAEL DEACONESS MEDICAL CENTER | 2009-07-09 | — | — | US | claimed |
| EP-1594507-A4 | NOVEL ANTIHERPES DRUG COMBINATIONS | UNIV MASSACHUSETTS (US) | 2008-10-01 | — | — | EP | claimed |
| WO-2007016450-A2 | METHODS FOR TREATING OR PREVENTING REACTIVATION OF A LATENT HERPESVIRUS INFECTION | BETH ISRAEL DEACONESS MEDICAL CENTER (US) | 2007-02-08 | — | — | WO | claimed |
| EP-1594507-A2 | NOVEL ANTIHERPES DRUG COMBINATIONS | The University of Massachussetts (US) | 2005-11-16 | — | — | EP | claimed |
| US-5756116-A | VIRICIDES USING ACYCLOVIR RESISTANT STRAIN OF HERPES VIRUS | HOSTETLER KARL Y (US) | 1998-05-26 | — | — | US | claimed |
| WO-1998018472-A1 | ANTIHERPETIC PHARMACEUTICAL COMPOSITIONS CONTAINING ACYCLOVIR FOR TOPICAL APPLICATORS | RECORDATI S.A. CHEMICAL AND PHARMACEUTICAL COMPANY (CH) | 1998-05-07 | — | — | WO | claimed |
| EP-0831794-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1998-04-01 | — | — | EP | claimed |
| EP-0746319-A4 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1997-11-05 | — | — | EP | claimed |
| WO-1997040056-A1 | PRODRUGS OF ACYCLOVIR | DRUG INNOVATION & DESIGN, INC. (US) | 1997-10-30 | — | — | WO | claimed |
| WO-1996040088-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1996-12-19 | — | — | WO | claimed |
| EP-0746319-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER, Karl Y. (US) | 1996-12-11 | — | — | EP | claimed |
| US-5580571-A | ACYCLOIR MONO OR DIPHOSPHATE; TOPICAL USE IN HERPES VIRUSINFECTIONS | HOSTETLER KARL Y (US) | 1996-12-03 | — | — | US | claimed |
| WO-1994026273-A1 | ACYCLOVIR DERIVATIVES FOR TOPICAL USE | HOSTETLER KARL Y (US) | 1994-11-24 | — | — | WO | claimed |
| US-4287188-A | PARTICULARLY 9-(2-HYDROXYETHOXYMETHYL) GUANINE MONOPHOSPHATE AND SALTS, USEFUL AS ANTIVIRIAL AGENTS | BURROUGHS WELLCOME CO. (US) | 1981-09-01 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150246137-A1 | LIPID COATED NANOPARTICLES CONTAINING AGENTS HAVING LOW AQUEOUS AND LIPID SOLUBILITIES AND METHODS THEREOF | LIPA, LIPC, LIPG | PNP 3215/4885BLM 3588/4885HBB 2877/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.